Antibodies

05 Sep 2017 TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial
05 Sep 2017 European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
02 Sep 2017 Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
02 Sep 2017 Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin)
01 Sep 2017 MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen
01 Sep 2017 Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414
31 Aug 2017 New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma
30 Aug 2017 FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
29 Aug 2017 FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
29 Aug 2017 Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer
29 Aug 2017 Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for Cyltezo™ (adalimumab-adbm), a biosimilar to Humira®, for the treatment of multiple chronic inflammatory diseases
29 Aug 2017 Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira® Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects
29 Aug 2017 New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels
29 Aug 2017 Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
28 Aug 2017 GeNeuro and Servier Announce Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis
28 Aug 2017 Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
28 Aug 2017 Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
28 Aug 2017 FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
26 Aug 2017 Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection
25 Aug 2017 Kyowa Hakko Kirin Co., Ltd.: US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the Treatment of Mycosis Fungoides and Sézary Syndrome
25 Aug 2017 IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union
24 Aug 2017 Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab’s Biologics License Application in the US
24 Aug 2017 Genmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple Myeloma
24 Aug 2017 Chugai’s Emicizumab Receives Priority Review Designation by FDA for Hemophilia A with Inhibitors
23 Aug 2017 Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top